Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 142 clinical trials
Evaluating the Clinical Value of Traditional Chinese Medicine in the Adjuvant Therapy of Triple-negative Breast Cancer

This is a prospective, single site, randomized, double-blind Phase III clinical trial to evaluate the clinical value of Traditional Chinese Medicine in the adjuvant therapy of triple-negative breast cancer patients.

oestrogen receptor
HER2
epidermal growth factor receptor
creatinine clearance rate
metastasis
  • 0 views
  • 19 Feb, 2024
Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy

This study will evaluate the efficacy and safety of antharcycline-based adjuvant chemotherapy compared with observation in triple negative breast cancer (TNBC) patients with residual invasive disease after platinum and taxanes based neoadjuvant chemotherapy.

renal disease
HER2
adenocarcinoma of the breast
cyclophosphamide
adjuvant chemotherapy
  • 0 views
  • 19 Feb, 2024
A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast

This is a open-labeled, single-arm, Investigator-initiated clinical trial of camrelizumab (an anti-PD-1 antibody) in combination with radiotherapy in patients with early triple-negative breast cancer. We will enroll 60 subjects. This study aims to evaluate the efficacy and safety of camrelizumab combined with radiotherapy in the treatment of early TNBC

HER2
serum pregnancy test
primary tumor
metastasis
12 lead electrocardiogram
  • 0 views
  • 19 Feb, 2024
A Long Term Follow-Up Study of Fabry Disease Subjects Treated With FLT190

Current treatment for Fabry disease is limited to the symptomatic management of pain, conventional management of complications, and methods to increase the availability of functional GLA. This clinical study aims to investigate the long-term safety and durability of GLA in patients who have been dosed with a new gene therapy …

breakdown
gene therapy
deficiency
glycosphingolipids
fabry's disease
  • 0 views
  • 19 Feb, 2024
Effectiveness and Acceptability of MINDFULNESS by Smartphone for Patients With Chronic Migraine and Medication Overuse

This preliminary study will be conducted on 25 patients that have been submitted to a withdrawal according to the standard procedure at our hospital and they will practice mindfulness daily by a standard session of 12 minutes on their smartphone recorded by the expert who generally manage their sessions at …

chronic migraine
migraine
therapeutic process
analgesia
  • 0 views
  • 19 Feb, 2024
NBE-002 in Patients With Advanced Solid Tumors

This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of NBE-002, a novel anti-ROR1 antibody-drug conjugate, in patients with advanced solid tumors.

advanced malignant solid tumor
serum pregnancy test
blood coagulation tests
progressive disease
triple-negative breast cancer
  • 0 views
  • 19 Feb, 2024
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative breast cancer (TNBC) that has spread, or metastasized, to other parts the body and is PD-L1-negative. The names of the study interventions involved in this study are: Sacituzumab govitecan (IMMU-132) Pembrolizumab (Keytruda; MK-3475)

HER2
immunostimulant
cns disease
metastasis
neuropathy
  • 8 views
  • 19 Feb, 2024
Ipatasertib + Atezolizumab to Prevent Recurrence in TNBC

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer in the breast or lymph nodes and have circulating tumor DNA in the blood. This research study involves the following investigational drugs: Ipatasertib Atezolizumab

HER2
treatment regimen
immunostimulant
axillary lymph node dissection
blood transfusion
  • 0 views
  • 19 Feb, 2024
Strain vs. Left Ventricular Ejection Fraction-based Cardiotoxicity Prevention in Breast Cancer

Comparing preventive effect of myocardial global longitudinal strain-based cardioprotective stragety (angiotensin receptor blocker prophylaxis) with left ventricular ejection fraction-based strategy in breast cancer patients treated with adjuvant trastuzumab.

cardiotoxicity
HER2
immunostimulant
angiotensin
trastuzumab
  • 0 views
  • 19 Feb, 2024
Radiotherapy 3 vs 6 Gy in Gonarthrosis and Coxarthrosis

Once the treatment is finished, patients will be assessed at 8 weeks. If pain does not improve, a re-irradiation will be performed. If the patients were treated with 3 Gy a new randomization will be performed (3 vs 6 Gy again).

osteoarthritis
  • 0 views
  • 19 Feb, 2024